WHITEHOUSE STATION, N.J., April 2 (UPI) -- Merck said Monday the U.S. Food and Drug Administration approved Janumet for the treatment of type 2 diabetes.
Janumet, which is a combination of Merck's Januvia and metformin, was approved to improve blood sugar control in adult diabetics who are not adequately controlled on metformin or Januvia alone.
"Janumet is the latest advance in Merck's longstanding commitment to developing effective medicines for type 2 diabetes," said Adam Schechter, president of Merck's U.S. human health division. "With Janumet and Januvia, Merck now has a growing family of products that provides physicians with important treatment options for patients with type 2 diabetes."
The approval was supported by a 24-week study involving 701 patients that showed those taking Janumet experienced greater reductions in A1C than those on metformin alone. More than twice as many patients achieved a A1C level of less than 7 percent compared with patients on metformin alone.
